Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study

Authors:	Pallawi Torka MD Othman S. Akhtar MD Nishitha M. Reddy MD Bora E. Baysal MD PhD Angela Kader BA CCRP Adrienne Groman MS Jenna Nichols RN MS CCRC Cory Mavis BS MS Joseph D. Tario PhD AnneMarie W. Block PhD Sheila N. J. Sait PhD Paola Ghione MD Suchitra Sundaram MD Eugene R. Przespolewski PharmD BCOP Alice Mohr FNP-C MSN Ian Lund PA-C Jessica Kostrewa NP Kenneth McWhite PA Joseph DeMarco PA Michael Johnson DNP BSN NP RN Andrea Darrall NP Rosh-Neke Thomas-Talley FNP-BC Paul K. Wallace PhD Vishala Neppalli MD Alan Hutson PhD Francisco J. Hernandez-Ilizaliturri MD

Affiliation:	1. Roswell Park Comprehensive Cancer Center, Buffalo, New York;2. Vanderbilt University Medical Center, Nashville, Tennessee;3. Icahn School of Medicine at Mount Sinai, New York, New York;4. University of Manitoba, Winnipeg, Manitoba, Canada

Abstract:

Keywords:	CD20 MIPI score monoclonal antibody p53 survival outcomes